MET and non-small cell lung carcinoma: Capmatinib is a highly specific MET inhibitor that has shown efficacy in clinical trials of NSCLC with MET exon 14 skipping mutations or MET amplification, especially in treatment‐naïve patients with MET exon 14 skipping mutations.21